openPR Logo
Press release

President of India visits CIGB today to reinforce bilateral trade and scientific cooperation

06-25-2018 10:21 AM CET | Politics, Law & Society

Press release from: Center for Genetic Engineering and Biotechnology

President of India visits CIGB today to reinforce bilateral

Havana, June 22nd, 2018 - The 14th and current President of India, in office since July 25th 2017, Ram Nath Kovind (b. 1945) visited the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. President Ram Nath Kovind was received by the President of BioCubaFarma, Dr. Eduardo Martínez, and the General Director of the CIGB Dr. Eulogio Pimentel. This is a very important date in the agenda of Mr. Ram Nath Kovind during the state visit to Cuba started yesterday to strengthen bilateral trade and cooperation. The visit environment harmonized with good political relationship between both countries, which date back to 1959 when India was one of the first countries to recognize the Cuban Revolution. This time, the visit of the President of India was preceded by visits of business executives from India to BioCubaFarma’s institutions, looking for updating and strengthening relations dating back to the 90s.

An outstanding precedent was the visit of the Minister of Commerce & Industry, Shri Suresh Prabhu, to CIGB in November 1rst, 2017 to appreciate the high research standards and advancement achieved by this institution. In that meeting at CIGB, Mr. Shri Suresh Prabhu reiterated the potential of cooperation between the Indian Pharmaceutical Industry and the CIGB to find affordable health solutions. The CIGB has been working with Indian companies and research institutions from the 90s when projects of technology transfer were successfully completed to manufacture cutting-edge biotech products in India. In addition, hundreds of Indian scientists have been speakers from 1983 at the “Cuban Seminars on Interferon” and the International Congress “Biotecnología Habana”, where exchange of experience, results and knowledge have been abundant between experts from more than 50 countries.

Written by: José A. Buxadó, Assistant Researcher, CIGB.
Foto: Jesús Seoane Herrera
Contact:
Alyane Vazquez González, BA.
Communication & Media
Centre for Genetic Engineering and Biotechnology
Ave 31 e/ 158 y 190, Playa, P.O. Box 6162,
Habana 10600, Cuba.
e-mail: alyane.vazquez@cigb.edu.cu.

The Centre for Genetic Engineering and Biotechnology (CIGB) is an institution with a dynamic development that has reached a high level of research, development, production, and commercialization of biologicals obtained by methods of modern biotechnology based on the most advanced concepts of quality. Its performance is projected on the research generating knowledge for developing new products, services, and commercial activity, supported by a quality system that insure customer satisfaction, taking into account environmental issues. Its impact is driven to human health, agriculture, aquiculture, and the environment. The CIGB is an institution devoted to applied and basic research of life science (Science, Nov. 27th, 1998: 1626). Discovery, development, production, and commercialization of products derived from Biotechnology are among its best known priorities (Nature, Apr. 1rst, 1999, 398 (6726): A22). A highly qualified staff of more than 1 600 employees transform into reality a part of what was just an idea several decades ago: developing an industry based on science in a developing country under serious economic limitations coming from an intensive foreign economic and financial pressure with extraterritorial features (The Economist, Nov 27th, 2003).

Contact:
Alyane Vazquez González, BA.
Communication & Media
Centre for Genetic Engineering and Biotechnology
Ave 31 e/ 158 y 190, Playa, P.O. Box 6162,
Habana 10600, Cuba.
e-mail: alyane.vazquez@cigb.edu.cu.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release President of India visits CIGB today to reinforce bilateral trade and scientific cooperation here

News-ID: 1094941 • Views: 1741

More Releases from Center for Genetic Engineering and Biotechnology

Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with
CIGB’s researchers defeat cancer once again
Havana – September 13, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce favorable results of an innovative medicine developed by Cuban researchers and engineers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba,
Approval for commercialization of Heberprot-P® in Mexico
Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing

All 4 Releases


More Releases for CIGB

Insulin Like Growth Factor I – Market Growth, Trends, Forecast and COVID-19 Im …
Insulin Like Growth Factor I – Market Growth, Trends, Forecast and COVID-19 Impacts (2014 - 2026) Global Market Monitor released the new market research report- “Insulin Like Growth Factor I – Market Growth, Trends, Forecast and COVID-19 Impacts (2014 - 2026)” – Shed light on the available opportunities and potential challenges that market players are facing along with in Insulin Like Growth Factor I market. Furthermore, the report is complemented by
Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with
CIGB’s researchers defeat cancer once again
Havana – September 13, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce favorable results of an innovative medicine developed by Cuban researchers and engineers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba,
Approval for commercialization of Heberprot-P® in Mexico
Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing
Global Insulin Like Growth Factor 1 Market Sales, Analysis, Growth & Forecast By …
A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global Insulin Like Growth Factor 1 Market Research Report (2017-2021)” which provides an outlook of current market value as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% during stated forecast from 2017-2022. The report studies the insulin like growth factor 1 market worldwide, especially in North America,
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1): H …
Market Research Hub (MRH) added a new research report to its vast database titled “Insulin like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Pipeline Review, H2 2017” Which Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor I- Pipeline Review, H2 2017, outlays comprehensive information on the